Convalescent Plasma News and Research

RSS

Recombinant protein vaccine stands up to SARS-CoV-2 variants

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 May 2022

Case report: human breast milk from vaccinated woman clears persistent SARS-CoV-2 infection

A new study published in the journal Viruses aimed to report the effects of plasma infusion and then breastmilk ingestion as a therapy for persistent SARS-CoV-2 infection in a patient with a common variable immunodeficiency (CVID) phenotype.

18 May 2022

CDC study of pregnant women hospitalized with COVID in 2021 found 93% not vaccinated

In a recent study posted to the Research Square* preprint server, researchers assessed the characteristics and treatment of coronavirus disease 2019 (COVID-19) in pregnant women.

12 May 2022

Severe symptoms result in high titers of SARS-CoV-2 antibodies

Scientists have focused on determining the cause-effect relationship between SARS-CoV-2 antibody titers and COVID-19 disease severity.

9 May 2022

Benefit from convalescent plasma shown in COVID outpatient trial

Researchers have conducted a double-blind, multicentre, randomized, controlled trial, which is known as Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Study to evaluate if early COVID-19 plasma treatment could reduce disease progression and, thereby, reduce hospitalization rate.

9 May 2022

Outcomes of COVID-19 treatment with Paxlovid

Researchers investigated the outcomes of COVID-19 treatment with paxlovid.

5 May 2022

The war against COVID-19: reinfection, vaccines, and herd immunity

A communication published in the journal Epidemiologia aimed to answer several questions concerning neutralizing antibodies against SARS-CoV-2, herd immunity, and COVID-19 vaccines.

4 May 2022

Phase 2 clinical trial of COVID-19 convalescent plasma with high antibody titers

Researchers determined the threshold neutralizing antibody titer for effective COVID-19 convalescent plasma therapy.

4 May 2022

Findings of the HITCH randomized clinical trial show lack of improvement in COVID-19 on temporary androgen suppression

Researchers investigated whether temporary androgen suppression by degarelix improved the clinical outcomes among male patients hospitalized with COVID-19.

27 Apr 2022

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Researchers investigated the interplay of all the factors responsible for within-host evolution of SARS-CoV-2 variants in immunocompromised patients.

21 Apr 2022

Waning antibody responses in SARS-CoV-2-infected children and adults over time

In a new study, researchers evaluated the duration of antibodies against SARS-CoV-2.

20 Apr 2022

New, longest documented case of persistent acute SARS-CoV-2 infection

Researchers describe a 16-month-old case of SARS-CoV-2 infection in an immunocompromised individual.

18 Apr 2022

Efficacy of SARS-CoV-2 hyperimmune globulin in treatment of severely immunocompromised hospitalized COVID-19 patients

Researchers conducted a controlled, double-blinded Phase III trial to evaluate the efficacy of SARS-CoV-2) hyperimmune globulin in immunocompromised hospitalized COVID-19 patients.

7 Apr 2022

Does COVID-19 vaccination benefit those with prior SARS-CoV-2 infection?

Researchers evaluate the effectiveness of four COVID-19 vaccines against symptomatic infection, hospitalization, and death in convalescent individuals.

5 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Convalescent plasma treatment for newly diagnosed COVID-19 patients may reduce hospitalization risk

Early treatment of newly diagnosed COVID-19 patients with plasma extracted from individuals who have recovered from the disease reduces the need for hospitalization by more than 50%, according to a new nationwide clinical trial.

31 Mar 2022

How the timing and dose of different types of passive antibody treatments predict protection from SARS-CoV-2 infection

A new study has focussed on conducting a systematic search of the literature and aggregated data associated with randomized control trials of passive antibody therapy.

25 Mar 2022

Detection of immune and clotting dysfunction in plasma and saliva after SARS-CoV-2 infection

It is becoming increasingly clear that individuals recovering from acute coronavirus disease (COVID-19) may develop post-acute sequelae (Post-Acute Coronavirus Syndrome, PACS).

23 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

Convalescent antibodies do not enhance SARS-CoV-2 infection

Researchers investigated whether antibodies enhance severe acute respiratory syndrome coronavirus-2 infection.

16 Mar 2022